Our end of the year message
HARMONY Alliance Research Project title: The impact of
Over 140 valued HARMONY Alliance community members joined
CLL-2: Exploring the occurrence of other malignancies
CLL: Delphi Survey Project: Towards a Core Outcome Set for Chronic ...
MM-2: Contextualizing clinical trials by developing robust historical ...
AML-5: Exploring a role for HARMONY data as historical control ...
AML-4: Using big data to confirm the link between MRD and survival ...
AML-3: Using big data to shed light on the clinical impact of ...
ALL-5: Exploring the prognostic significance of minimal residual ...
ALL-4: Harnessing the Power of Big Data to Predict Outcomes
ALL-3: Exploring treatment patterns and outcomes in older adult ...
MM: Delphi Survey Project: Towards a Core Outcome Set for Multiple ...
HARMONY
Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands